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Abstract 
 
 
Machine learning (ML), artificial intelligence (AI) and other modern statistical methods are 
providing new opportunities to operationalize previously untapped and rapidly growing sources of data for 
patient benefit. Whilst there is a lot of promising research currently being undertaken, the literature as a 
whole lacks: transparency; clear reporting to facilitate replicability; exploration for potential ethical 
concerns; and, clear demonstrations of effectiveness. There are many reasons for why these issues exist, 
but one of the most important that we provide a preliminary solution for here is the current lack of ML/AI-
specific best practice guidance. Although there is no consensus on what best practice looks in this field, we 
believe that interdisciplinary groups pursuing research and impact projects in the ML/AI for health domain 
would benefit from answering a series of questions based on the important issues that exist when 
undertaking work of this nature. Here we present 20 questions that span the entire project life cycle, from 
inception, data analysis, and model evaluation, to implementation, as a means to facilitate project planning 
and post-hoc (structured) independent evaluation. By beginning to answer these questions in different 
settings, we can start to understand what constitutes a good answer, and we expect that the resulting 
discussion will be central to developing an international consensus framework for transparent, replicable, 
ethical and effective research in artificial intelligence (AI-TREE) for health. 
 
  
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Machine learning (ML), artificial intelligence (AI) and other modern statistical methods are providing 
new opportunities to operationalize previously untapped and rapidly growing sources of data for patient benefit. 
The potential uses include improving diagnostic accuracy [1], more reliably predicting prognosis [2], targeting 
 
  
 
treatments [3], and increasing the operational efficiency of health systems [4]. Examples of potentially 
disruptive technology with early promise include image-based diagnostic applications of ML/AI, which have 
shown the most early clinical promise (e.g. deep learning-based algorithms significantly improving accuracy in 
diagnosing retinal pathology compared to that of specialist physicians [5]), or natural language processing used 
as a tool to extract information from structured and unstructured (i.e. free) text embedded in electronic health 
records (e.g. patients’ notes) which has also shown great potential [2]. Although, we are only just beginning to 
understand the wealth of opportunities afforded by these methods, there is growing concern in the academic 
community that because the products of these methods are not perceived in the same way as other medical 
interventions (e.g. pharmacological therapies), they do not have well-defined guidelines for development and 
use and rarely undergo the same degree of scrutiny. 
The Need for Guidance Today 
Increasingly clinicians are involved in the process of generating, using and interpreting clinical 
applications of machine learning and artificial intelligence. This has highlighted a series of fundamental issues 
that need to be addressed for clinicians and policy-makers to be able to make informed decisions about which 
tools are likely to be safe and effective. While many best practice recommendations for design, conduct, 
analysis, reporting, impact assessment and clinical implementation can be borrowed from the traditional 
biostatistics and medical statistics literature (e.g. [6]), they are not sufficient to guide the use of ML/AI research. 
Several high profile publications have demonstrated that there is a lack of transparency [7,8], replicability [9], 
ethics [10] & effectiveness [11] (TREE) in the reporting & assessment of ML/AI-based prediction models. 
Furthermore, nearly all biomedical research publications using ML/AI are reported in a ‘positive’ light, 
however, there are currently few examples, if any, of health-related ML/AI algorithms that have conclusively 
demonstrated improved patient outcomes. So how do we (i.e. clinicians, methodologists, statisticians, data 
scientists, and healthcare policy maker), identify and critique relevant ML/AI research to assess its suitability for 
translation from the ‘computer-bench’ to the bedside? Currently, such assessments are difficult because we lack 
guidance on what differentiates good from bad at the different stages of the healthcare-related ML/AI 
development pipeline, from design and data analysis, through to reporting, and evaluation of 
effectiveness/impact on health. Producing such guidance is a major undertaking due to the ever-growing battery 
of ML/AI algorithms and the multifaceted nature of assessing performance and clinical impact. Not taking 
action is unacceptable, and if we wait for a more definitive solution, we risk wasting valuable work [12-16], 
whilst allowing futile research to continue unchecked, or worse, translation of ineffective (or even harmful) 
algorithms into clinical practice.  
 
 
 
An Initial Framework - 20 Critical Questions for Health-related ML/AI Technology (Box 1) 
 Ensuring any potential guidance is applicable to all relevant stakeholders in this emerging field requires 
representatives of each part of the health data-science cycle (Figure 1) to be involved in its creation. Here we 
propose a series of critical questions to help identify common pitfalls which can undermine ML/AI-based 
applications in health. These questions arose as a result of a dialogue between a group of UK-based and 
international organisations spanning a range of different perspectives, from statutory regulators and national 
advisory bodies, to academic organisations, including:  
 
  
 
● The UK’s National Data Science Institute (The Alan Turing Institute [17]), established 2015;  
● The UK’s Health Data Science at Scale Initiative (HDR UK [18]), established 2018; 
● The UK’s National Institute for Clinical and Care Excellence (NICE [19]); established in 1999; 
● The UK’s Medicines and Healthcare products Regulatory Agency (MHRA [20])), established in 2003 
(as a merger of the Medicines Control Agency (MCA) and the Medical Devices Agency (MDA)); 
● The UK’s Clinical Practice Research Datalink (CPRD [21]), supported by the Medicines and 
Healthcare products Regulatory Agency and National Institute of Health Research, is a UK 
Government research service providing anonymised UK primary care data research since the late 
1980s. 
● The Enhancing the Quality and Transparency of Health Research (EQUATOR) Network [22], 
established in 2006;  
● The Meta-Research Innovation Centre at Stanford (METRICS) [23], established in 2014; 
● The Data Science for Social Good (DSSG) Program [24], established in 2013 and run by the Centre for 
Data Science and Public Policy at the University of Chicago 
 
Initial discussions regarding the principles on which standards for ML research might be based 
identified a series of themes central to high quality health-related research and technologies: transparency, 
replicability, ethics & effectiveness (TREE). Based on these themes, we have developed an initial framework - 
20 critical questions (Box 1) which can be used as a guide. The questions are not only relevant for those who 
use the findings (i.e. patients and policy makers), but also those who generate ML/AI health research. For the 
former group these questions might inform development of critical appraisal and reporting guidelines. For the 
latter, these questions might inform the way that research groups design and conduct such research. We hope 
that adoption of this framework, and other related publication which are in the pipeline e.g. NHS-England’s AI 
Code of Conduct [25], will help to build trust in the underlying processes and results of health-related ML/AI 
research.  
 
 
 
 
 
 
 
Figure 1: The Data Science Cycle for Healthcare 
 
  
 
 
 
Figure 1 Legend: This figure summarises the stages relevant for and affected by ML/AI methods and 
their adoption in clinical care. The collaborative effort behind this piece represents all stages required for 
developing transparent, reproducible, ethical and effective ML/AI solutions for clinical care. For almost all 
projects this process will not be linear from start to finish, rather, requiring a continuous feedback loop between 
the different stakeholders responsible for the various tasks. Starting with the vital input for any algorithmic 
solution, data, this can be generated either via planned experiments or collected during routine clinical practice. 
Given the data, the necessary data guardians then need to assess any proposed projects, provide the necessary 
access and oversee the users' activities in order to ensure the safe and efficient use of data. The research and 
development phase puts an idea into practice, and provides examinable proof that an algorithm indeed 
accomplishes the stated goals. Whether a solution is truly fit for purpose (i.e. transparent, reproducible, ethical 
and effective) should be first assessed by independent bodies. Finally, the performance of the ML/AI solutions 
should be continually monitored to demonstrate that it remains effective in improving patient outcomes, after it 
becomes recommended standard practice. The implementation of any new algorithm will influence the data 
collected at the level of care, by assigning increased importance in those features that are used as model inputs, 
whilst generating new information (i.e. the model outcomes) in routine practice, thus completing the 
development cycle, and initiating a new cycle.  
 
 
 
Box 1: 20 Critical Questions for Health-related ML/AI Technology 
Overall Project-specific Question 
 
  
 
1) How is the ML/AI model embedded in feedback loops as part of a learning health system? 
 
Inception-specific Questions 
2) What is the health question relating to patient benefit? 
3) When and how should patients be involved in data collection, analysis, deployment, and use?   
4) Is there organisational transparency about the flow of data?   
 
Analysis-specific Questions 
5) Is the data suitable to answer the clinical question, i.e. does it capture the relevant real-world 
heterogeneity, and is it of sufficient detail and quality? 
6) Does the methodology reflect the real-world constraints and operational procedures associated with data 
collection and storage? 
7) On what basis are data accessible to other researchers?  
8) What computational and software resources are available, and are they sufficient to tackle this problem? 
9) Are the reported performance metrics relevant for the clinical context in which the model will be used? 
10) Is the reported gain in statistical performance with the ML/AI algorithm clinically justified in the context 
of any trade-offs?  
11) Is the ML/AI algorithm compared to the current best technology, and against other appropriate 
baselines?  
12) Are the different parts of the prediction modelling pipeline available to others to allow for methods 
reproducibility, including: the statistical code for ‘pre-processing’, and the modelling workflow 
(including the methods, parameters, random seeds, etc. utilised)? 
13) Are the results reproducible in settings beyond where the system was developed (i.e. external validity)? 
 
Impact Evaluation-specific Questions 
14) What evidence is there that the model does not create or exacerbate inequities in healthcare by age, sex, 
ethnicity or other protected characteristics?   
15)  What evidence is there that clinicians and patients find the model and its output (reasonably) 
interpretable?  
16) What evidence is there of real world model effectiveness in the proposed clinical setting? 
 
Implementation-specific Questions 
17) Is the model being regularly re-assessed, and updated as data quality and clinical practice changes (i.e. 
post-deployment monitoring)?  
18) Is the ML/AI model cost-effective to build, implement, and maintain?  
19) How will the potential financial benefits be distributed if the ML/AI model is commercialized?   
20) How have the regulatory requirements for accreditation/approval been addressed? 
 
20 Critical Questions 
Overall Project-specific Question 
 
 
  
 
1. How is the ML/AI model embedded in feedback loops to facilitate a learning health system? 
‘Lone wolf’ ML/AI may occasionally promote innovation; however, it is being increasingly recognised 
that such research needs to be seen in a wider organizational context to be made most useful. This context is best 
understood as a learning health system in which data science is used to inform clinical decision making (and 
health system operations) in an iterative feedback loop; a move away from the classical framework of a linear 
pathway with an ‘end user’. 
At the local level, this involves a range of steps to achieve clinical adoption, including: integration into 
current IT systems, human resources, financial investment, etc. At the societal level, the ML/AI ‘revolution’  in 
health has resulted in major organizational change, including new national research organisations and initiatives 
in the UK (e.g. Alan Turing Institute [17], & Health Data Research UK [18]), new national initiatives (e.g. NHS 
workforce Topol review [26]), updated health technology assessment regulation (e.g. [27,28]), readiness 
preparation of guidance developers (e.g. NICE [19]) and the growth of a new (global) industrial sector (e.g. 
Google DeepMind, Benevolent AI, Babylon), as well as partnerships between health systems (e.g. The 
European Health Data Network [29]). Understanding to what extent these different organisations are engaged in 
a given piece of ML/AI research may help elucidate the pathways to impact in clinical practice. In summary, 
researchers should be cognisant of the path from development to implementation, as well as be able to describe 
which parts of the healthcare data science cycle their proposed research engages with. This doesn't preclude 
proof of concept work that may only occupy a small angle of the healthcare data science cycle, but equally this 
should be stated up front. 
 
 
Inception-specific Questions 
 
2. What is the health question relating to patient benefit? 
The vast majority of published clinical prediction models are never used in clinical practice [30]. One 
reason for this is the lack of a specific clinical decision making process which the model may meaningfully 
inform or optimise; simply predicting future events on their own does not help a clinician do anything 
differently. In other words; just because we can, doesn’t mean we should. Clarity is needed at the outset of 
research on the potential use of a proposed model (i.e., what the consequent actions would be, based on the 
model outcome and what patient outcomes are they improving), whether any underlying trade-offs that arise 
from the use of the model are in fact justified by the additional benefits provided by it and the likelihood of 
successful deployment in clinical practice. 
 
3. When and how should patients be involved in data collection, analysis, deployment, and use?   
With the growing use of routinely collected individual participant data (in addition to researcher 
collected data) often with an alternative legal basis (i.e. legitimate interests) to individual consent, it is more 
important now than ever, that patient and public involvement (PPI) is at the centre of the health data science 
cycle (figure 1). The responsibility of researchers to involve individuals whose data is being utilised in decisions 
about the use of said data has been highlighted by new legislation in Europe (GDPR), as well as the national 
standards for public involvement in research [31]. PPI can be at multiple stages in data science cycle, including 
but not limited to: identifying the need for an AI/ML algorithm, supporting the development of the algorithm, 
and determining the acceptability of the algorithm in practice. The exemption from seeking individual consent, 
 
  
 
does not mean that the researchers are exempt from engaging patients and public altogether, and thus, at the 
heart of every healthcare ML/AI project should be a clear understanding of the acceptability of the proposed 
model and outcomes to those from whom the data was collected, the users (i.e. clinicians) and the impacted 
individuals (i.e. those for whom the model will be used to inform clinical management).  
 
4. Is there organisational transparency about the flow of data?   
Patients have strong views about transparency in the flow of data, and how their data is secured [32]. 
For patients and their clinicians to trust ML/AI models it is important that they understand the interactions 
which led to the development of the model, whether they are between organisations in the public, not for profit 
and industrial sectors, or within them (e.g. transfer from one hospital department to another). Complying with 
the aforementioned legislative frameworks (e.g. GDPR) whilst necessary, is not sufficient to demonstrate the 
transparency required to produce trustworthy ML/AI research. The degree of detail necessary will differ 
depending on the institutions involved, and the nature of the work being undertaken. Therefore, the 
responsibility lies with ML/AI algorithm developers and those involved in accessing, transferring, or storing the 
data, to engage key stakeholders to understand what is required in each particular case. One aspect of the 
reporting procedure that can help ensure transparency regarding the aforementioned interactions is the inclusion 
of clear declarations of interest by all involved parties. 
 
 
Analysis-specific Questions 
 
5. Is the data suitable to answer the clinical question, i.e. does it capture the relevant real-world 
heterogeneity, and is it of sufficient detail and quality? 
The key question here is whether it is possible to answer the clinical question with the data available. 
For example, a dataset not containing the (known) relevant/important predictors of an outcome, is unlikely to 
satisfactorily answer questions about it. No ML/AI algorithm can produce something from nothing - this is 
worth pointing out as often there is an implicit belief to the contrary where it specifically concerns ML and AI 
algorithms. Data accuracy, sampling of participants, eligibility criteria, and missing data, also need to be 
considered when assessing the potential of developing useful and generalizable ML/AI algorithms. If data are 
available, but they are of poor quality or not relevant, it is unlikely that a good ML/AI application can be 
developed.  
One should also consider the likelihood of failure when operating outside the training data range, e.g., 
an image-recognition/self-driving-car-decision-making system may fail when encountering for the first time a 
cyclist at night. Hence it is important to check whether the data- including timescale, heterogeneity (differences 
in data collection e.g.  measuring devices, compliance), population, and situation - is in accordance with, and 
representative of, the envisioned clinical application scenario. These are just some of the issues that need to be 
addressed in determining whether the data are of sufficient quality and detail to be able to inform the clinical 
question of interest. However, every point around the health data science cycle (Figure 1) can inform the data 
collection mechanism and thus can be improved iteratively.  
 
6. Does the validation methodology reflect the real-world constraints and operational procedures 
associated with data collection and storage? 
 
  
 
Increasingly ML/AI research is making use of routinely collected data, including: data that exists as 
part of the health system (including electronic health records, clinical imaging, and genomic information); civil 
administrative data (e.g. death records, and educational achievement); and data from mobile and wearable 
devices (e.g. [33]). Information from these sources can arrive in batches, or via a continuous stream, and is often 
stored in different locations requiring reconciliation and collation, which in and of itself introduces a delay in 
when specific pieces of data are available for use. In contrast to these real-world constraints, ML/AI algorithms 
are often validated on historical data, yielding performance guarantees only under the assumption that the data 
generating process does not change, e.g., over time, or across hospitals. In practice, these assumptions are often 
severely violated and result in ML/AI models underperforming in deployment when compared to performance 
reported during system development [34]. A robust validation methodology in medicine and healthcare (and in 
most application areas of ML/AI) usually needs to take time into account and create temporally disjoint training 
and test sets [35,36] which account for how the data is collected and stored.  
 
 
7. On what basis are data accessible to other researchers?  
Data sharing is not an endpoint in itself but rather a means to enhance, verify and distribute the 
knowledge generated by the ML/AI algorithm [37] and thus is closely related to reproducibility and 
replicability. Most major funding sources now require applicants to outline a data management and data sharing 
plan; this can entail among other things, storing the data in a convenient format along with a data dictionary, a 
long-term archiving plan, and providing an independent access mechanism (e.g. a university ethics committee, 
or a R&D department). Where data used to develop the ML/AI algorithm have been accessed via national data 
custodians (e.g. CPRD [21]. NHS Digital [38], HQIP [39]), there are clear data access processes in place for 
independent validation by other researchers. Additionally, data sharing can be undertaken using a wide range of 
mechanisms, including: 
1. Making the data available in open repositories such as datadryad.org [40] (after being anonymised 
using tools such as Amnesia [41]), or restricted access repositories such as UK data Archive [42]; 
2. Signing data sharing agreements; 
3. Providing remote access to local computing facilities where the data is stored, as is possible with 
specific restricted access data enclaves such as NORC at the University of Chicago [43], and the 
electronic Data Research and Innovation Service (eDRIS) [44]. 
The advent of these facilities means that there are fewer reasons to be unable to share data from publicly funded 
research with other researchers. As such, ML/AI algorithm development should be accompanied by clear 
statements of what tools and mechanism will be used to support access to the data utilised, for the purposes of 
replication and validation of reported results. 
 
8. What computational and software resources are available, and are they sufficient to tackle this 
problem? 
There are many areas of health-related prediction modelling where it is common to work with millions 
of parameters, such as image-based deep learning [45], and statistical genetics [46]. As such, it has become 
common practice to not only determine the complexity of the data one is working with, but also the 
computational resources available, because much more often than with traditional statistical models, the latter 
can be the limiting factor in determining what analyses can be undertaken [47]. Simply put, in some situations 
 
  
 
more computational resources may in fact allow one to train a better model. For example, without compute 
servers with GPUs it is infeasible to even attempt to use complex neural network-based models, especially since 
these large-scale models require additional complex operations (e.g. regularisation) to prevent overfitting 
[48,49]. Similar issues can arise when using secure compute environments such as data enclaves or data safe 
havens, where the relevant software frameworks might not be available and thus would warrant implementation 
from scratch, or where there are limits to the computational resources available. Ideally, analysis would not be 
limited by the availability of computational resources, but developers need to understand the constraints within 
which they are working so that any analysis can be tailored to requirements. Furthermore, it is also important to 
understand the implications of using specific software, as the underlying licence can have far reaching 
consequences on the commercial potential and other aspects of the algorithms future (see [50] for a brief 
overview of software licencing for scientist-programmers). 
 
9. Are the reported performance metrics relevant for the clinical context in which the model will be 
used? 
The choice of metric matters in order to translate good performance in the (training data) evaluation 
setup to good performance in the eventual clinical setting with patient benefit. This discrepancy in model 
performance may arise for multiple reasons, but the most common of which being that the evaluation metrics 
are not good proxies for demonstrating improved outcomes for patients (e.g. misclassification error for a 
screening application with imbalanced classes). Another common mistake is choosing a performance metric 
which is vaguely related to, but not indicative or demonstrative of improved clinical outcomes for patients. For 
example, IBM’s Watson expert system (Watson For Oncology (WFO) [51]), is used in several hospitals around 
the world to support decision making. However, published works describing WFO do not report relevant 
statistical (e.g. discrimination, calibration, etc.), and clinically-oriented (e.g. net benefit type) performance 
metrics. Instead they focus on concordance (true positive rate where the ground truth is provided by physician, 
i.e.  the proportion of cases where WFO’s recommendation agrees with that of the treating physician [e.g. 52-
54]). Determining which is the appropriate performance metric to report will depend not only on the statistical 
task, but also the clinical decision making process to which the results will be applied, as such, it is important 
that all relevant parties (e.g. patients, data scientists, clinicians, etc.) are consulted in the selection process.  
 
10.Is the reported gain in statistical performance with the ML/AI algorithm clinically justified in the 
context of any trade-offs?  
For a new diagnostic or prognostic tool to be justified for routine use, it must offer a clinically 
meaningful advantage over existing approaches in addressing a specific need [55], which requires the use of an 
appropriate performance metric as discussed previously. Whilst necessary, the presence of a clinically 
meaningful advantage alone is not sufficient justification, as any improvement must be weighed against the cost 
of any changes it necessitates (e.g. the resource requirement to collect additional data). A recent paper published 
by Google investigating the accuracy of deep learning methods in combination with electronic health records for 
predicting mortality, readmission and length of stay is an apt demonstration of why this point is so important 
[2]. In their appendix, the authors provide a comparison of their deep learning (DL) model against a logistic 
regression model.  The AUC improvement reported for each of the three tasks ranged from 0.01 to 0.02. If we 
assume that all caveats pertaining to statistical significance, and the sufficiency of the reported metric for 
making this next decision are met, the question that must therefore be asked is - whether the marginal gain of 
 
  
 
implementing a complex AI/ML solution is worth it, and is the need any more effectively addressed by the deep 
learning model? Whilst the answer to that question will certainly be situation specific, any proposed use case 
will (at minimum) need to justify the following: 1) the cost of developing, deploying, utilising, and maintaining 
a deep learning model such as the one described relative to the improvement observed; and 2) the need for 
additional subsidiary models to clawback inferential capabilities lost in the transition away from a model with 
human interpretable coefficients (white-box). 
 
11. Is the ML/AI algorithm compared to the current best technology, and against other appropriate 
baselines?  
ML/AI algorithms can be viewed as health technologies, and at the design stage consideration should 
be given to the currently used approach that the algorithm may replace. For almost all clinical questions, there 
will be a well-accepted “standard approach” from decades of biostatistics research, e.g. proportional hazards 
models for survival modelling. For many clinical outcomes and settings, there will be existing, published 
models. Similarly, there will be model proxies for uninformed guessing, such as predicting the majority class in 
a classification task. One common way to exaggerate the benefit of AI/ML approaches is to avoid any 
comparison of AI/ML against null models or the currently used approach, and instead compare to sub-par 
competitors (including in appropriately or weakly developed statistical models), or to avoid a comparison 
altogether. This “weak comparator”/“strawman” bias has been generally demonstrated in reports of (traditional) 
new vs existing prognostic models [49]. One such example comes from a systematic review of proposed 
modifications to the Framingham risk score for predicting the risk of a heart attack within 10 years; the review 
found that most proposed alternatives had flaws in their design, analyses, and reporting that cast doubt on the 
reliability of the claims for improved prediction [56]. The parallels to pseudo-scientific argumentation vs 
evidence-based medicine are especially noteworthy, as they make potential flaws relatively easy to spot to a 
medical practitioner, e.g., it is instructive for this purpose to replace “treatment” with “algorithm”, and “best 
practice” with “gold standard”. 
  
12. Are the different parts of the prediction modelling pipeline available to others to allow for methods 
reproducibility [57], including: the statistical code for ‘pre-processing’, and the modelling workflow 
(including the methods, parameters, random seeds, etc. utilised)? 
Reproducibility of research has become a growing concern across many scientific domains [58,59], and 
in the ML/AI field, access to the underlying code and raw data is central to preventing and mitigating 
reproducibility concerns. A recent example of how concerns regarding reproducibility in medical modelling 
research have manifested comes from a review of studies published using the MIT critical care database, 
MIMIC, which illustrates the degree to which inadequate reporting can impact replication in the prediction 
modelling [9]. Specifically, the reproducibility issues that have been identified in the literature occur not only in 
attempts to re-create reported findings, but also in how authors report data characteristics, such as the inclusion 
and exclusion criteria used to arrive at the final population of interest. In the review, 28 studies based on the 
same core data set (MIMIC) predicting mortality were investigated, and two important results were identified: 
For more than half of the studies examined the reproduced sample size differed by more than 25% from the 
reported sample size due to insufficiently clear descriptions of the inclusion/exclusion criteria. The result of 
inadequate reporting was that in the replication, the use of off-the-shelf logistic regression and boosted trees on 
the reproduced samples, produced better results in 64% and 82% of the 28 studies respectively, than the ML/AI 
 
  
 
model reported in the original study. These issues could have been easily avoided by providing the project code, 
specifically that relating to data cleaning and pre-processing. It should be noted that the RECORD reporting 
guidelines for studies using routinely collected health data already recommend providing detailed information to 
this effect [60], and there are several potential solutions that exist to facilitate this process, including code 
sharing and project curation platforms such GitHub. 
 
13. Are the results reproducible in settings beyond where the system was developed (i.e. external validity 
[61])? 
 It has become increasingly evident that there is a relative lack of validation studies for diagnostic and 
prognostic tools, which precedes the emergence of the ML/AI era [62]. Even when external validation studies 
are carried out, reductions in the predictive accuracy of models, relative to their original (development study) 
performance is expected [34,63]. Systematic reviews have repeatedly observed this latter phenomenon in the 
applications of classical statistical models to a variety of healthcare-related prediction tasks, from mortality-risk 
prediction in acute kidney injury patients [64], to falls risk prediction in the elderly [65]. It is unclear to what 
degree this phenomenon associated with results reproducibility (i.e. “replication,” that is, the production of 
corroborating results in a new study, having followed the same experimental methods [66]), is a consequence of 
the inadequate reporting that has been observed in the modelling literature [61], or other related issues. Given 
the additional complexities introduced by ML/AI algorithms, it is important that developers play a proactive role 
in ensuring that sufficient information is provided to allow their models to undergo rigorous, but fair [67], 
external validation (ideally by independent investigators). 
  
 
Impact Evaluation-specific Questions 
 
14. What evidence is there that the model does not create or exacerbate inequities in healthcare by age, 
sex, ethnicity or other protected characteristics?   
Systematic testing for bias and fairness is the first step in making informed model selection decisions to 
minimize inequities that could be caused by the use of ML/AI algorithms [68]. One way in which ML/AI 
algorithms result in bias is by making disproportionate errors in different populations. Depending on how the 
AI/ML algorithm has been developed (including whether key populations, defined by sex, age, ethnicity are 
sufficiently represented in the data, and included in the training of the algorithm), can influence the predictive 
accuracy of the algorithm in different subgroups, and thus when these predictions are used to take actions on 
individuals, they can create or exacerbate inequities [69]. The issue of data that is not truly representative of the 
entire target population is particularly important [70], as it highlights the importance of fairness considerations 
at every point in the data science cycle (figure 1), from data collection/research to implementation and 
evaluation. Other examples of how these issues can manifest in the real world can be found in ProPublica’s 
analysis of the COMPAS recidivism prediction tool [10] and the USAs diabetes screening criterion [71], which 
both illustrate variation in performance of an algorithm based on race.  
It will often be the case that many of the ML/AI algorithms developed will indeed have bias, but it is 
important to compare that to the bias in the existing systems being used. The types of performance variation that 
need to be investigated for depend on the consequent actions (or ‘interventions’) that the algorithm is helping to 
 
  
 
decide between. If the interventions are very expensive or have unwanted side-effects, then we would want to 
minimize disparities in the number of false positive predictions from different subgroups, to prevent 
unnecessary harm. If the interventions are predominantly assistive, we should be more concerned with 
disparities in false negatives, to prevent individuals missing out on a potentially beneficial input. It is worth 
noting that the explanation above presupposes that a decision threshold has been set, which may sometimes be 
outside of a developer’s remit. However, this does not exempt them from needing to demonstrate that when 
using ‘sensible’ thresholds, that the algorithm does not create or exacerbate inequalities. In fact, there have been 
several methodological developments in the area of fairness evaluation to support this type of analysis [e.g. 
72.73], and it is important that machine learning/AI developers and health practitioners engage with these tools.  
 
15. What evidence is there that clinicians and patients find the model and its output (reasonably) 
interpretable? 
Clinical adoption of an algorithm depends on two main factors, its usefulness (i.e. clinical utility), and 
its trustworthiness. When the outputs of a prediction model do not directly answer a specific clinical question it 
ultimately limits its usefulness, as discussed in earlier questions; whereas models whose processing pipeline is 
difficult to explain and justify to a general audience will invariably limit the trust placed in its outputs [74], 
despite robust and demonstrated statistical gains. However, trust is not the only reason that interpretability in 
important [75]. Recent changes in legislation (e.g. GDPR) have introduced additional protections for 
individuals, including a right to an explanation for how a decision was made, where it pertains them [76], 
thereby creating a legal requirement to provide insight into the underlying decision-making process an algorithm 
learns.  
We alluded to the interpretability-performance trade-off in question 11, as it pertains to weighing up 
the loss of interpretability in transitioning from a ‘white-box’ to ‘black-box’ model, in exchange for improved 
performance. However, as the authors of the deep learning for EHR study recognised and attempted [2], there 
are partial solutions, including both model-specific and model agnostic methods, which can be used to claw 
back interpretability when using ML/AI methods [77]. Given that legal and moral burden of explanation to 
establish trust will vary with the nature of the decision, i.e. applications of ML/AI in health that influence the 
allocation of potentially life-prolonging treatments will necessitate a much higher explanatory burden to satisfy 
those individuals who are affected, the sufficiency of any explanations and adequacy of any insight producing 
method  can only be determined through consultation and collaboration with the end users (clinicians), and 
target audience (patients). 
 
16. What evidence is there of real world model effectiveness in the proposed clinical setting and how are 
unintended consequences prevented? 
ML/AI tools often carry the misleading aura of self-evident advanced technology and this falsely limits 
the perceived need for careful validation and verification of their performance, clinical and overall utility once 
they begin being used in the routine clinical practice. A recent systematic review demonstrated that only a 
couple of hundred randomized clinical trials (out of a total of almost a million) examined how the use of 
diagnostic tests affected clinical outcomes [78], and therefore demonstrated their clinical utility. From the 
ML/AI domain, the experience of Babylon Health’s symptom checker-based triaging illustrates a similar point. 
In early testing with patient focus groups there were concern that there might be “[...] gaming [of] the symptom 
 
  
 
checker to achieve a GP appointment” [4]; an illustration of how algorithms are not always used as intended in 
the real world, and that these factors need to be assessed using pragmatic clinical trials [79].  
 This is further complicated by the fact that if ML/AI algorithms do not qualify as medical devices (as 
not all do), they are not subject to regulatory approval, and thus a large incentive to demonstrate their real world 
effectiveness is absent. The important consequence to be aware of in these situations, is the potential for patients 
[80], and the health systems in which the algorithm is utilised, being left exposed to unintended consequences. 
For example, a recently released heart age calculator appears to prompt all individuals over the age of 30, 
regardless of the absence of any additional risk factors, to visit their general practitioner to have their cholesterol 
and blood pressure checked [81]. The overwhelming concern is that this could result in a substantial increase in 
the number of visits to primary care physicians, in a situation where the evidence for the benefits this may reap 
have previously been found to be inadequate by the UK’s healthcare guidance developing body [82]. 
  
 
Implementation-specific Questions 
 
17. How is the model being regularly re-assessed, and updated as data quality and clinical practice 
changes (i.e. post-license monitoring)?  
Even when there is sufficient evidence of efficacy and real-world effectiveness of a model to endorse 
its widespread use in clinical practice, it is important to recognise that the effectiveness requires constant review 
given the dynamic landscape of the healthcare environment. For example, computer-aided diagnosis programs 
have become an integral part of breast cancer screening programs around the world since the FDA first 
approved one for use in 1998 [83], but are they still as useful as they were 20 years ago? Most of the 
commercially available tools are based on neural networks which identify regions of interest, and diagnose the 
identified abnormality (e.g. calcification or mass). Early studies demonstrated modest increases in detection 
rates of breast cancer using CAD, compared to clinicians working without the aid of a CAD system [1,84]. 
However, almost 20 years following the FDA’s first license for a mammography-based CAD system, national 
registry-based studies have produced sobering results, illustrating no significant improvement in diagnostic 
accuracy associated with CAD use in mammography interpretation [85]. Moreover, researchers have recently 
demonstrated that incorrect prompts from mammography-based CAD systems can actually decrease the 
sensitivity of more discerning users by up to 0.145 (95% CI, 0.034-0.257) for difficult cases [86]. Whilst the 
work discussed is not a comprehensive review of CAD in breast cancer, the results clearly suggest that there is a 
need to constantly re-evaluate technologies, as their usefulness can change over time. Other changes that might 
impact the healthcare landscape, include: changes in the case-mix of the population (e.g. demographic & 
eligibility changes), and improvements in treatments. 
 
18. Is the ML/AI model cost-effective to build, implement, and maintain?  
While ML/AI algorithms may offer transformational benefits to healthcare systems and patients, there 
are significant costs associated with the development of software, the generation and use of data, 
implementation of a new system in practice, and acting on the additional information provided. Understanding 
the potential clinical benefit of new models - over and above current practice - alongside the cost (or savings) 
introduced by utilising these models should form part of any healthcare decision maker’s appraisal of ML/AI-
based technologies. Effective appraisal will require the development of assessment frameworks that take into 
 
  
 
account both the evidence for effectiveness and the evidence for economic impact. This is an area where 
healthcare decision makers, such as NICE, the FDA, etc., are crucial, as they can help developers of ML/AI 
models by providing clear guidance on the appropriate evidence that should be generated to demonstrate both 
effectiveness and economic impact, including: credible evidence relating to technical accuracy of the models, 
the relevant outcomes that demonstrate clinical effectiveness in general practice and, as appropriate, evidence to 
inform decision makers on the budget impact or the cost-effectiveness. 
 
19. How will the potential financial benefits be distributed if the ML/AI model is commercialized?   
Like all technologies ML/AI algorithms may have a market value. In situations where 
commercialisation is a goal, it is important to remember that health systems, and governmental research 
funding, can make a substantial contribution to the creation of an algorithm, via the associated sunk costs, such 
as data acquisition (clinicians’ time, scanners, etc.), data annotation (training clinicians who eventually interpret 
the data generated), and sometimes even the developers’ time (i.e. when they are publically funded researchers). 
In a publicly funded health system this even more important, as the symbiotic relationship between data-
generating institutions and those with the capabilities to create AI/ML algorithms, is only possible because of 
expectation that benefits arising from the use of data will be retained (to some degree) by the health system, 
thereby satisfying the social contract with the public. Therefore, it is not only important to ensure that the 
investment and contributions of a health system and/or institution to an algorithm is recognised, but also that a 
mechanism be put in place to compensate them for having done so.  
 
20. How have the regulatory requirements for accreditation/approval been addressed? 
 Software products including ML/AI algorithms can be subject to numerous regulatory requirements, 
depending on the setting in which the product will be used, from research and development to placing the 
product on the market (See box 2 for a high-level overview of the UK’s regulatory framework). In our 
experience, whilst most clinicians are aware of CE marking of physical devices (the regulatory framework in the 
EU and the UK), its application to software products can often be a surprise. This is also true of software 
developers. Given that the regulatory landscape for health-related ML/AI-based software has changed 
dramatically over the last decade, and will continue to respond dynamically to innovation for the foreseeable 
future, it is important that discussions regarding the regulatory requirements for products in development are 
made early in the planning process. However, having this conversation once is clearly not sufficient, for 
example, devices that are developed and used in-house (in the UK) are not currently subject to device 
regulations, but this will change in 2020 when new updated regulations apply [27,28], and as such, regular 
review of regulatory compliance is necessary. 
 
 
Conclusion: from critical questions to a consensus TREE framework  
In much the same way that over previous decades’ clinicians have been aided by frameworks for 
evaluating the strength of evidence, the ML/AI field should usefully build on what has been learned in 
traditional statistical approaches for ‘clinical evidence’ and the quality assurance pipeline (e.g. [6], [30], [90-94]. 
However, as we show here some of the challenges are new and different. Encouraging patients, clinicians, 
academics, and all manner of healthcare decision makers to ask the challenging questions raised by the TREE 
framework we propose here, will hopefully contribute to the development of safe and effective ML/AI-based 
 
  
 
tools in healthcare. By beginning to answer these questions in different settings, we can start to understand what 
constitutes a good answer, and we expect that the resulting discussion will be central to developing an 
international consensus framework for robust decision making in ML/AI at every stage of the research, 
translation, and application process in advanced ‘health and wellbeing’ data science. Developing such a 
framework will involve many challenges, including: finding common terminology (where key terms partly or 
fully overlap in meaning; balancing the need for robust empirical evidence of effectiveness without stifling 
innovation; identifying how best to manage the many open questions regarding best practices of development 
and communication of results; the role of different venues of communication and reporting; whilst 
simultaneously providing sufficiently detailed advice to produce actionable guidance for non-experts; and 
balancing the need for transparency against the risk of undermining IP rights. The path to a definitive solution 
will undoubtedly be long, and complex, but with the questions detailed above, we would argue that we have 
taken a step in the right direction. The next step will be to undertake a more comprehensive review of each of 
the 20 questions, to establish what is known with certainty, where the literature is lacking, and to identify high 
priority issues for the community to focus on. For those who would like to join us in this endeavour, we offer an 
open invitation to participate in the development of this AI-TREE framework. 
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Box 2: A High-Level Overview of The UK’s Regulatory Framework 
for ML/AI Algorithms in Health 
Developers need to determine whether their ML/AI algorithm falls under the Medical Device 
Regulations’ remit [87], which until 2010 did not regulate independent software products. These regulations 
cover products that make claims with a medical nature such as: providing diagnostic information; making 
recommendations for therapy; or, providing risk predictions of disease. The MHRA has published guidance for 
developers that covers this in greater detail [88]. If an algorithm does fall within the remit of the aforementioned 
regulation, the developer must then seek regulatory approval/accreditation in the form of a “CE” mark, prior to 
marketing it.  
To CE mark an algorithm, the developer must follow one of the applicable conformity assessment 
routes, which, for the medium and high risk products, will require the involvement of a ‘Notified Body’ to assure 
the process. The developer must ensure that the device meets the relevant ‘Essential Requirements’ before 
applying the CE mark. These requirements include: 
• Benefits to the patient shall outweigh any risks. 
• Manufacture and design shall take account of the generally acknowledged state of the art. 
• Devices shall achieve the performance intended by the manufacturer 
• Software must be validated according to the state of the art taking into account the principles of 
development lifecycle, risk management, validation and verification 
• Confirmation of conformity must be based on clinical data. Evaluation of this data must follow a defined 
and methodologically sound procedure. 
In addition to the above, manufacturers are required to have post market surveillance provision to review 
experience gained from device use and to apply any necessary corrective actions. 
 Moreover, the use of ML/AI algorithms may be regulated indirectly by other legislation or regulatory 
agencies. Perhaps the highest profile additional legislative framework to be aware of is the EU General Data 
Protection Regulations (GDPR), the relevance of which has been discussed elsewhere (questions 3 and 16). In 
terms of other regulatory agencies who play an important role in the regulation of ML/AI software in health, the 
UK’s Care Quality Commission (CQC) is one group to be aware of, as they are tasked with monitoring 
compliance with NHS Digital’s Clinical risk management standards [89]; a contractual requirement placed on 
developers engaging in service provision to the NHS.    
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